Active — Not RecruitingNot Applicable

Role of ROS and cAMP-PKA Biomarkers in ADPKD

United States100 participantsStarted 2023-07-01

Plain-language summary

The primary objective is to determine the prognostic value of markers of ROS and cAMP-PKA signaling to assess disease severity and progression in patients with ADPKD.

Who can participate

Age range15 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Male and female subjects 15 - 70 years of age * Previous diagnosis of ADPKD (based on Ravine et al. criteria) * Class 1 A-E according to imaging classification * estimated GFR\> 45 mL/min/1.73 m2 (CKD-EPI) * Ability to provide written, informed consent Exclusion Criteria: * Class 2, according to imaging classification * A concomitant systemic disease affecting the kidney * Diabetes mellitus * Predicted urine protein excretion in \>1 g/24 hrs. and or abnormal urinalysis * Use of antioxidants, i.e., vitamins, Nrf2 activators * Patients who are part of an interventional study or taking tolvaptan

What they're measuring

Change in height adjusted Total kidney volume (htTKV)

Timeframe: Baseline to 24 months

Change in eGFR

Timeframe: Baseline to 24 months

Baseline concentration of: NOX4, biochemical markers related to ROS, mitochondrial injury and metabolites as predictors of change in TKV and eGFR

Timeframe: Baseline to 24 months

Trial details

NCT IDNCT07217158

SponsorMayo Clinic

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-03-31

View on ClinicalTrials.gov More Autosomal Dominant Polycystic Kidney Disease trials